We are excited to be hosting a ZOOM Video Webinar Presentation and Q&A Session with Dr. Dietrich A. Stephan Ph.D. the Chairman & CEO, Founder of NeuBase Therapeutics (NBSE) on Tuesday, December 22nd beginning at 8:30 am pacific / 11:30 am eastern.
Dr. Dietrich A. Stephan, Ph.D. is the Chairman & CEO, Founder of NeuBase Therapeutics, Inc. (NASDAQ: NBSE). He is an industry veteran who is considered one of the fathers of the field of precision medicine, having trained with the leadership of the Human Genome Project at the NIH and then going on to lead discovery research at the Translational Genomics Research Institute and serve as professor and chairman of the Department of Human Genetics at the University of Pittsburgh. Stephan has identified the molecular basis of dozens of genetic diseases and published extensively in journals such as Science, the New England Journal of Medicine, Nature Genetics, PNAS, and Cell. In parallel, Dr. Stephan has founded or co-founded 14 biotechnology companies and has advised an additional 12 companies. These companies are backed by top-tier investors such as Sequoia Capital, KPCB, Thiel Capital, and Khosla Ventures as well as corporate partners such as Life Technologies, Pfizer, and Mayo Clinic. Dr. Stephan received his Ph.D. from the University of Pittsburgh and his B.S. from Carnegie Mellon University.
NeuBase Therapeutics is developing the next generation of gene silencing therapies with its flexible, highly specific synthetic antisense oligonucleotides.
Last week, NeuBase announced positive in vitro and in vivo preclinical data for its PATrOL™-enabled anti-gene therapies for the treatment of myotonic dystrophy type 1 (DM1). These new data show that PATrOL-enabled Compound A can rapidly resolve mis-splicing without negatively impacting DMPK protein levels. They also support the potential of NeuBase’s anti-gene approach to comprehensively treat the underlying cause of DM1.
Learn more today at https://www.neubasetherapeutics.com
We will have limited seats for this event as we have a nice group confirmed already, so please reply quickly.